Skip to main content

15-04-2016 | Lymphoma | News | Article

News in brief

Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma

medwireNews: Patients with cutaneous T-cell lymphoma (CTCL) who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology.

The histone deacetylase inhibitor is usually administered via infusions on days 1, 8 and 15 of a 28-day cycle. But patients who responded to standard therapy could be switched to a reduced dosing schedule – once every other week and eventually to once a month – at the physician’s discretion.

Of 38 patients with mycosis fungoides or Sézary syndrome included in this medical review, 17 received romidepsin for longer than 6 months, with a median duration of treatment exposure of 15 months, report Joan Guitart (Northwestern University, Chicago, Illinois, USA) and co-workers.

Nine of these long-term responders received the dose-sparing regimen, with three patients achieving complete remission and the remaining six attaining a partial response.

This approach “allows for maintaining response, tolerability, and convenience”, say the researchers, adding that it “may offer a new option to prolong response in a disease notorious for short responses.”

But they conclude that the results need validation in prospective trials.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits